What happened with SYRE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Spyre Therapeutics is developing medicines for inflammatory bowel disease and rheumatic diseases, with its candidates still in clinical development. Its bowel-disease program tests SPY001, SPY002 and SPY003 individually and in two-antibody combinations that target different inflammatory pathways. It is also developing SPY072 for rheumatic diseases. These antibodies are designed to remain in the body longer, with the aim of reducing how often patients need maintenance injections.
Spyre has no approved products and earns no product-sales revenue. It relies on financing to support development and expects to raise further equity or debt capital. If its candidates receive regulatory approval, it plans to sell them in the United States and other key markets itself, through partners, or both. Future sales would depend on clinicians prescribing the medicines and government and private payors covering and reimbursing treatment.
Spyre outsources manufacturing and related drug-supply activities. WuXi Biologics provides development, manufacturing and testing services for its core bowel-disease programs, which currently have sole-source supply relationships. Spyre is building additional manufacturing capabilities through third parties outside China, including in the United States.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond this list, watch Roche’s competing TL1A program and WuXi Biologics’ support for reliable clinical manufacturing as Spyre builds supply alternatives outside China.
Xencor’s XmAb942 competes with Spyre’s SPY002 to treat inflammatory bowel disease by blocking TL1A, making XmAb942 trial results a direct comparison to watch. Xencor also earns payments from partners that license its drug candidates for further development and potential sale.
Merck’s tulisokibart competes directly with Spyre’s SPY002: both are clinical-stage antibodies targeting TL1A for inflammatory bowel disease. Merck already sells medicines to wholesalers, hospitals and healthcare providers; tulisokibart trial results, rather than its overall sales, are the relevant comparison for Spyre.
Teva’s duvakitug competes with Spyre’s SPY002 by targeting TL1A to treat inflammatory bowel disease. Teva earns revenue from generic and innovative medicines as well as manufacturing and licensing; duvakitug’s clinical progress is the part to watch for Spyre.
Sanofi and Teva’s TL1A antibody program competes with Spyre’s SPY002 for inflammatory bowel disease, so its trial progress matters to Spyre’s competitive position. Sanofi develops medicines and vaccines and sells vaccines worldwide, including to publicly funded international organizations.
Takeda’s top-selling Entyvio is an established competitor for Spyre’s SPY001: it treats ulcerative colitis and Crohn’s disease through the same α4β7 mechanism. Spyre aims to distinguish its candidate with less frequent dosing.
AbbVie competes with Spyre on two fronts: its marketed inflammatory bowel disease medicines face Spyre’s investigational IL-23 treatments, while its ABBV-701 TL1A program rivals Spyre’s TL1A candidates.
Shattuck Labs offers a competing approach to Spyre’s TL1A antibodies for immune-mediated diseases: Shattuck blocks the receiving side of the inflammatory signal, DR3, while Spyre blocks the signal molecule, TL1A.
Oruka’s ORKA-001 can inform the case for Spyre’s SPY003 because both seek long-lasting IL-23p19 blockade, though Oruka targets psoriasis and Spyre targets inflammatory bowel disease. Watch whether ORKA-001 maintains efficacy with infrequent dosing; Oruka has no approved products or revenue yet.
Johnson & Johnson’s IL-23 treatments for inflammatory bowel disease and its JNJ-2113 development program compete with Spyre’s investigational IL-23 antibody and antibody combinations. Johnson & Johnson already sells prescription medicines to retailers, wholesalers, hospitals and healthcare professionals.
Palisade Bio’s oral PALI-2108 seeks to treat the same ulcerative colitis and Crohn’s disease patients as Spyre’s antibodies, but works by inhibiting PDE4 locally in the lower intestine. Neither has established commercial capabilities; PALI-2108’s efficacy and tolerability results are the comparison to watch against Spyre’s long-acting approach.
Pfizer’s marketed Xeljanz and Pelsipity compete for ulcerative colitis patients whom Spyre aims to treat with its investigational inflammatory bowel disease antibodies.
Fed Interest Rate Decision
Spyre’s Fed rate decision matters because it can change the interest earned as its $756.5 million in cash, cash equivalents and marketable securities is reinvested, as well as the cost of any new borrowing.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is above expectations, Spyre may earn more interest as investments mature and are reinvested, but any new borrowing could cost more.
If it comes in below expectations
If the policy rate is below expectations, Spyre may earn less interest as investments mature and are reinvested, while any new borrowing could cost less.
Merck & Co., Inc. earningsMRK
If Merck’s report gives trial updates on tulisokibart, readers can see how this direct TL1A-antibody rival compares with Spyre’s SPY002 for inflammatory bowel disease.
Watch whether tulisokibart advances in trials and what its efficacy and safety results show. It and SPY002 both target TL1A for inflammatory bowel disease. Strong progress would add clinical support for the target while giving Spyre a more formidable direct rival; setbacks would leave Spyre with a less advanced competitor to benchmark against, but would not validate SPY002.
Spyre Therapeutics, Inc. earningsThis company
Spyre Therapeutics has no approved products or product-sales revenue, so its report will show what it spent advancing clinical programs and how much cash remains to fund them.
Read research and development spending alongside cash, cash equivalents and marketable securities. Continued program progress with controlled spending and ample funds would mean the current resources can support more development; rising spending and faster cash use would bring financing closer, and financing could dilute existing shareholders.
